Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
ORIGINAL ARTICLES UROLOGY
Minerva Urologica e Nefrologica 2016 June;68(3):263-9
Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma
Hakan ÖZTÜRK ✉
Department of Urology, School of Medicine, Sifa University, Izmir, Turkey
BACKGROUND: The aim of this paper was to review the diagnostic contributions of 18FDG-PET/CT to the restaging of renal cell carcinoma (RCC) retrospectively.
METHODS: The current study included 132 patients, who were operated on between July 2007 and April 2013, for renal cell carcinoma (RCC) and received 18FDG-PET/CT scans for restaging purposes. Ninety (68.2%) of the patients were male and 42 (31.8%) were female, with a mean age of 60.7 years and standard deviation ±11.9 (range min: 28, max: 86). The patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after the intravenous injection of 555 MBq of F-18 FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up.
RESULTS: Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18FDG-PET/CT were 93.8%, 88.2%, 92.6%, 88.2%, and 91.6%, respectively.
CONCLUSIONS: 18FDG-PET/CT can detect local and distant metastases with high precision in the restaging of RCC. It can play an important role in the postoperative decision-making for treatment choices, in following treatment response, and can affect decision-making.